InnoCare Optoelectronics Corporation (TPE:6861)
129.00
-14.00 (-9.79%)
Nov 20, 2026, 1:30 PM CST
InnoCare Optoelectronics Revenue
InnoCare Optoelectronics had revenue of 874.21M TWD in the quarter ending September 30, 2026, with 57.56% growth. This brings the company's total for the last twelve months to 3.07B, up 40.99% year-over-year. In the year 2025, InnoCare Optoelectronics had annual revenue of 2.29B with 15.29% growth. That makes InnoCare Optoelectronics the 23,249th largest company in the world by revenue and 989th in Taiwan.
Revenue (ttm)
3.07B
Revenue Growth
+40.99%
P/S Ratio
1.75
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.37B
Revenue by Geography
- Asia 1.55B 67.6%
- America 475.93M 20.7%
- Europe 203.61M 8.9%
- Taiwan 56.05M 2.4%
- Africa 8.07M 0.4%
Fiscal year ended Dec 31, 2025 See the full InnoCare Optoelectronics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.29B | 304.13M | 15.29% |
| Dec 31, 2024 | 1.99B | 152.55M | 8.30% |
| Dec 31, 2023 | 1.84B | -49.50M | -2.62% |
| Dec 31, 2022 | 1.89B | -54.14M | -2.79% |
| Dec 31, 2021 | 1.94B | -416.96M | -17.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| United Orthopedic | 6.10B |
| Hi-Clearance | 4.51B |
| TaiDoc Technology | 4.32B |
| Wellell | 2.56B |
| Apex Biotechnology | 1.86B |
| Dynamic Medical Technologies | 1.42B |
| WeLeader Biomedical | 1.27B |
| A Plus Biotechnology | 919.38M |
InnoCare Optoelectronics News
- 2 months ago - InnoCare Optoelectronics Slides: Investor presentation - Filings
- 3 months ago - InnoCare Optoelectronics Quarterly report: Q1 2026 - Filings
- 3 months ago - InnoCare Optoelectronics Quarterly report: Q2 2026 - Filings